FOLEY & LARDNER LLP

FOLEY & LARDNER LLP
ATTORNEYS AT LAW

WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 600
WASHINGTON, D.C. 20007-5143
202.672.5300 TEL
202.672.5399 FAX
www.foley.com
WRITER'S DIRECT LINE
202.672.5430
drosen@foley.com EMAIL

September 2, 2021

VIA REGULATIONS.GOV

Division of Dockets Management
U.S. Food and Drug Administration
Department of Health and Human Services
Room 1061, HFA-305,
5630 Fishers Lane,
Rockville, MD 20852

RE: Withdrawal of Petition; Docket No. FDA-2019-P-3024

Dear Sir or Madam:

This Petitioner hereby requests withdrawal of the above-referenced citizen petition requesting that the Commissioner of the Food and Drug Administration declare that:

> Sitagliptin Capsules Eq. 25 mg base, Eq. 50 mg base and Eq. 100 mg base are suitable for submission as an Abbreviated New Drug Application (ANDA), pursuant to 21 CFR § 314.94.

Sincerely yours,

David L. Rosen, B.S. Pharm., JD